The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil
Chronic lymphocytic leukaemia is a slow-growing leukaemia of developing B-lymphocytes, which may transform to an aggressive lymphoma known as Richter’s syndrome. While Richter’s syndrome can present in untreated or relapsed-refractory cases, it may occur upon the commencement of less intensity treat...
| Published in: | Case Reports in Hematology |
|---|---|
| Main Authors: | Teng Fong Ng, Benedict Carnley, Celia Green, Dominic Spagnolo, Michael F. Leahy |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2020/8363427 |
Similar Items
P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
by: J. P. Sharman, et al.
Published: (2022-06-01)
by: J. P. Sharman, et al.
Published: (2022-06-01)
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
by: Natali Pflug, et al.
Published: (2021-12-01)
by: Natali Pflug, et al.
Published: (2021-12-01)
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
by: Carol Moreno, et al.
Published: (2022-01-01)
by: Carol Moreno, et al.
Published: (2022-01-01)
A Novel Treatment With Obinutuzumab-Chlorambucil in a Patient With B-Cell Prolymphocytic Leukemia: A Case Report and Review of the Literature
by: Jason Hew MD, et al.
Published: (2018-07-01)
by: Jason Hew MD, et al.
Published: (2018-07-01)
Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia
by: Nicole Bourrier, et al.
Published: (2022-02-01)
by: Nicole Bourrier, et al.
Published: (2022-02-01)
Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter’s transformation: results from the phase II GIVeRS trial
by: Tamar Tadmor, et al.
Published: (2026-05-01)
by: Tamar Tadmor, et al.
Published: (2026-05-01)
Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases
by: Igor Aurer, et al.
Published: (2024-12-01)
by: Igor Aurer, et al.
Published: (2024-12-01)
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
by: Alessandra Tedeschi, et al.
Published: (2020-04-01)
by: Alessandra Tedeschi, et al.
Published: (2020-04-01)
S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
by: Anna Maria Frustaci, et al.
Published: (2023-08-01)
by: Anna Maria Frustaci, et al.
Published: (2023-08-01)
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
by: Andrea Visentin, et al.
Published: (2022-11-01)
by: Andrea Visentin, et al.
Published: (2022-11-01)
PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
by: T. Byalik, et al.
Published: (2022-06-01)
by: T. Byalik, et al.
Published: (2022-06-01)
PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
by: Tatyana Byalik, et al.
Published: (2023-08-01)
by: Tatyana Byalik, et al.
Published: (2023-08-01)
Chlorambucil-Induced Acute Interstitial Pneumonitis
by: Hammad Shafqat, et al.
Published: (2014-01-01)
by: Hammad Shafqat, et al.
Published: (2014-01-01)
Rapid desensitization for chlorambucil drug fever
by: E Weber, et al.
Published: (2007-07-01)
by: E Weber, et al.
Published: (2007-07-01)
Extranodal Richter's syndrome of the urinary bladder
by: Almudena Carrión-Valencia, et al.
Published: (2018-01-01)
by: Almudena Carrión-Valencia, et al.
Published: (2018-01-01)
The involvement of microRNA in the pathogenesis of Richter syndrome
by: Katrien Van Roosbroeck, et al.
Published: (2019-05-01)
by: Katrien Van Roosbroeck, et al.
Published: (2019-05-01)
Nasal Lymphoma with Low Mitotic Index in Three Cats Treated with Chlorambucil and Prednisolone
by: Karen W. L. Ng, et al.
Published: (2022-09-01)
by: Karen W. L. Ng, et al.
Published: (2022-09-01)
Biology and Treatment of Richter Transformation
by: Adalgisa Condoluci, et al.
Published: (2022-03-01)
by: Adalgisa Condoluci, et al.
Published: (2022-03-01)
Richter's transformation presenting with superior vena cava syndrome
by: Nuri Karadurmus, et al.
Published: (2017-07-01)
by: Nuri Karadurmus, et al.
Published: (2017-07-01)
Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome
by: Yifan Li, et al.
Published: (2026-06-01)
by: Yifan Li, et al.
Published: (2026-06-01)
Disseminated Enteroviral Infection Associated with Obinutuzumab
by: Claire Dendle, et al.
Published: (2015-09-01)
by: Claire Dendle, et al.
Published: (2015-09-01)
Peter Richter – notice
Published: (2017-03-01)
Published: (2017-03-01)
Hérnia de Richter
by: Ana Beatriz Esteves Batista, et al.
Published: (2019-12-01)
by: Ana Beatriz Esteves Batista, et al.
Published: (2019-12-01)
Ugi reaction in the synthesis of Janus dendrimers as nanocarriers of chlorambucil and ibuprofen
by: Israel Barajas-Mendoza, et al.
Published: (2025-07-01)
by: Israel Barajas-Mendoza, et al.
Published: (2025-07-01)
Chlorambucil-Bearing Hybrid Molecules in the Development of Potential Anticancer Agents
by: Sijongesonke Peter, et al.
Published: (2023-09-01)
by: Sijongesonke Peter, et al.
Published: (2023-09-01)
Chlorambucil combination therapy in refractory serpiginous choroiditis: A cure?
by: Arash Maleki, et al.
Published: (2021-03-01)
by: Arash Maleki, et al.
Published: (2021-03-01)
Research advances of obinutuzumab in the treatment of membranous nephropathy
by: Xiao-jing Lin, et al.
Published: (2024-01-01)
by: Xiao-jing Lin, et al.
Published: (2024-01-01)
The clinical development of obinutuzumab for the treatment of follicular lymphoma
by: Ma B, et al.
Published: (2017-04-01)
by: Ma B, et al.
Published: (2017-04-01)
PB1860: CLONALITY RELATEDNESS AND MOLECULAR CHARACTERISTICS OF RICHTER SYNDROME
by: Y. Sha, et al.
Published: (2022-06-01)
by: Y. Sha, et al.
Published: (2022-06-01)
Chlorambucil-Loaded Graphene-Oxide-Based Nano-Vesicles for Cancer Therapy
by: Surabhi Kumari, et al.
Published: (2023-02-01)
by: Surabhi Kumari, et al.
Published: (2023-02-01)
Synthesis, Characterization, and Cytotoxicity Evaluation of Chlorambucil-Functionalized Mesoporous Silica Nanoparticles
by: Juliana Camila Fischer Karnopp, et al.
Published: (2024-08-01)
by: Juliana Camila Fischer Karnopp, et al.
Published: (2024-08-01)
Retrospective Safety Evaluation of Combined Chlorambucil and Toceranib for the Treatment of Different Solid Tumours in Dogs
by: Yuk-Yin Lai, et al.
Published: (2024-11-01)
by: Yuk-Yin Lai, et al.
Published: (2024-11-01)
Successful rescue treatment using chlorambucil for presumed recurrence of sinonasal lymphoma in a cat
by: Sho Goto, et al.
Published: (2023-03-01)
by: Sho Goto, et al.
Published: (2023-03-01)
Cytogenomic features of Richter transformation
by: Renata Woroniecka, et al.
Published: (2023-11-01)
by: Renata Woroniecka, et al.
Published: (2023-11-01)
Der Edelmann als Richter
by: Sabine Werthmann
Published: (2002-01-01)
by: Sabine Werthmann
Published: (2002-01-01)
Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Eliana MC Tacconi, et al.
Published: (2019-05-01)
by: Eliana MC Tacconi, et al.
Published: (2019-05-01)
Obinutuzumab treatment for antineutrophil cytoplasmic antibody-associated vasculitis
by: Chen Ye, et al.
Published: (2026-05-01)
by: Chen Ye, et al.
Published: (2026-05-01)
Secondary Hemophagocytic Syndrome Associated with Richter’s Transformation in Chronic Lymphocytic Leukemia
by: Nura El-Haj, et al.
Published: (2014-01-01)
by: Nura El-Haj, et al.
Published: (2014-01-01)
Similar Items
-
P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
by: J. P. Sharman, et al.
Published: (2022-06-01) -
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
by: Natali Pflug, et al.
Published: (2021-12-01) -
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01) -
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01) -
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
by: Carol Moreno, et al.
Published: (2022-01-01)
